DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed publication entitled: ...

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

Arquitos returned 29.6% net of fees and expenses in 2024, compared to 25.0% for the S&P 500. Click here to read the full letter.

At the beginning of the STS session, an informal audience poll suggested more prostacyclin users in the room at a 60-40 show of hands. "Cost still pretty much favors the prostacyclin," observed ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

The disorder often leads to death and strikes more women than men. Winrevair competes with Johnson & Johnson’s prostacyclin receptor agonist blockbuster Uptravi, as well as J&J’s endothelin ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...

Normally, these nasty effects are kept in check by another chemical called prostacyclin. But prostacyclin is made, in part, with the help of Cox-2 enzymes -- the enzymes that drugs like Celebrex ...

However, no vasodilators other than vardenafil were permitted at least 3 months before or during the study. In particular, prostacyclin analogues, bosentan and sildenafil were not given to any patient ...

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis of ROIV stock.

Meloxicam is an enolcarboxamide with preferential COX-2 activity. Studies conducted on experimental models and human tissues indicate that meloxicam is a more potent inhibitor of COX-2 than COX-1 ...